Association between Serum Gamma-glutamyl Transferase and Metabolic Syndrome: A Case–control Study

Abstract

Abstract Background: When gamma-glutamyl transferase (GGT) enzyme levels are measured using a GGT assay, a high result is indicative of liver disease and bile duct damage. The relation of GGT with metabolic syndrome (MetS) was specifically examined through the present study, where MetS comprises a group of metabolic illnesses, such as diabetes mellitus, dyslipidemia, and hypertension, which can cause cardiovascular morbidity and death. Consequently, a better prognosis would arise from the use of the GGT test for MetS patients. Materials and Methods: For this study, around 166 participants were enrolled equally in the two groups denoted as case and control groups. This study was performed by the inclusion of participants with and without MetS. All the laboratory tests were undertaken after approval from the Ethical Committee, and data were analyzed by the application of statistics. Results: According to statistics, most patients in the present study had a mean age of 40–60 years. According to the body mass index, while 51 people in the control group were within the normal range, 32 were determined to be obese. Compared to controls who had no comorbidities, the majority of patients had comorbidities. Statistically significant (P = 0.001) levels of serum GGT enzyme of over 40 U/L were found in 45 cases. Conclusion: There is an interdependence between the GGT levels and MetS as was drawn from the findings of this study. Making this test readily available will educate doctors about prescribing these tests at an early stage to morbid people and improving their lives with better outcomes, which will lower the likelihood of future health concerns.